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ABSTRACT 
 
Pre-eclampsia and eclampsia are major health problems in developing countries. MgSO4  is the standard 
drug in the control of convulsions in eclampsia. Our study carried out at PDVVPF’s hospital is based on 
the low dose regimen than Pritchard, which is suitable for Indian women who are of smaller built than 
women  in  western  world.  This  prospective  study  included  50  eclampsia  patients  receiving  low  dose  
MgSO4 therapy. The loading dose of MgSO4 was 9gm. Following this 2.5 gm was given intramuscularly 
every 6 hourly for 24 hours after administration of the loading dose. Patients were monitored hourly by 
observing their respiratory rate, knee jerk and urine output. Out of 50, two patients required Pritchard 
regimen, rest completely recovered from eclampsia. The maternal and perinatal morbidity and mortality 
were  comparable  to  those  of  the  standard  Pritchard  regime. The  study  did  not  find  a  single case of 
magnesium related toxicity with low dose MgSO4  regime. Low dose magnesium sulphate regime was 
found to be safe and effective in eclampsia. 
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INTRODUCTION 
 
Eclampsia  is  a  common  cause  of  maternal 
mortality worldwide particularly in the developing 
countries. It is estimated that every year eclampsia 
is associated with about  50,000 maternal deaths 
worldwide,  most  of  which  occur  in  developing 
countries.
1  The  incidence  of  eclampsia  in  our 
country  varies  from  0.5%-1.8%.  The  major 
breakthrough  in  the  management  of  eclampsia 
came  when  Dr.  J.  A.  Pritchard  published  his 
standardized MgSO4  treatment regime in 1984. 
The  collaborative  Eclampsia  Trial  which  was  a 
large  multicentric  trial  in  27  centres  in  9 
developing countries, found magnesium sulphate 
to be a better anticonvulsant in the management of 
eclamptic  seizures  when compared to phenytoin 
and  diazepam.
2  There  has  been  a  constant 
discussion  in  literature  regarding  dose  of 
Magnesium  sulphate  and  therapeutic  serum 
Magnesium  levels.  J  A  Pritchard  commented 
that if a woman is known to be or appear to be 
small, the dose should probably be limited.
3 Winit 
Phauapradit et al commented that is appropriate to 
take into account body weight when considering 
the dosage of drug for Asian women with body 
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weight  less  than  7okg.  The  aim  of  the  present 
study  was  to  evaluate  the  effectiveness  of  low 
dose magnesium sulfate in control of convulsions 
in  eclampsia,  to  assess  the  magnesium  related 
toxicity and to analyze the maternal and perinatal 
outcome. 
  
MATERIALS AND METHODS 
 
During the study period of 2009 to 2011, at Dr. 
Padmashree  Vithalrao  Vikhe  Patil  Hospital,  50 
cases of antepartum eclampsia were included  in 
the present study after human ethical committee 
approval.  Patients  with  a  history  of  generalized 
tonic-clonic convulsions, elevated blood pressure 
and proteinuria with no previous history of seizure 
disorders  like  epilepsy  were  included  in  the 
present study. Patients were excluded from study 
if there was doubt about the diagnosis because the 
accompanying  relatives  did  not  witness  the 
seizure, there was no elevated blood pressure on 
admission  or  had  received  diazepam  as 
anticonvulsant  prior  to  admission.  After  taking 
written  informed consent from each patient that 
fulfilled  the  inclusion  criteria  patients  received 
loading dose of 4 grams of magnesium sulphate 
(20%)  i.v.  with  2.5  grams  (50%)  i.m.  in  each 
buttock.  Subsequently,  maintenance  dose  of  2.5 
grams (50%) was given i.m. in alternate buttock 
every 6 hours up to 24 hours after delivery or after 
last convulsion, whichever was later. Serum Mg
++ 
level was measured 12 hours after the first dose. If 
convulsions were not controlled by the low dose 
regime, then the case was shifted to the standard 
Pritchard  regime.  Patients  were  monitored  for 
respiratory rate, Urine output (30ml/ hour) & deep 
tendon reflexes same as that of Pritchard regimen. 
All the principles of management of eclampsia are 
followed.  After  stabilization  of  patients,  labour 
was induced or augmented. Cesarean section was 
performed for obstetric indications. 
 
RESULTS 
 
During  the  study  period,  57  (2.4%)  cases  of 
antepartum eclampsia were noted among the 2375 
deliveries. Among these, 50 cases were included 
in the study. Most of the patients (36 cases; 72%) 
had not  taken  antenatal care. The patients  were  
from 17 years to 35 years with a mean age of 21 
years. 78% cases were primigravidas. 
The total dose of  magnesium  sulphate, required 
for control of convulsions was less than 20 grams 
ie.56.82%  less  than  that  is  required  in  standard 
Pritchard  regime.  The  serum  magnesium  levels 
were  monitored  in  all  cases  for  evidence  of 
magnesium toxicity. The mean serum magnesium 
value  ranged between 4.1  to 4.35meq/lit  during 
the  low  dose  regime.  There  was  no  maternal 
mortality due to eclampsia or its complication in 
the present study. In present study Microsoft excel 
was used for statistical analysis. 
 
 
Table: 1. Comparison of our regime with Pritchard’s  regime 
   MgSO4  regime  Pritchard’s  regime 
Control of convulsions  96% 
 
93.33% 
  Recurrence Rate  4%  6.67% 
Cases requiring a shift to the 
standard Pritchardt regime 
4%  - 
Perinatal mortality  12%  33.84% 
Serum Magnesium level  4.1 to 4.35meq/lit  3.74-6.14mg/dl 
Signs of drug toxicity  0  2% 
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Table:2. Comparison of total dose of MgSO4 in different regimes 
 
Name of regime  Pritchard 
regime 
Low dose 
Padhar regime 
Low dose 
Dhaka regime 
 MgSO4  low dose 
regime 
Loading dose  MgSO4  (20%)  IV  4gm  3gm  4gm  4gm 
Loading dose  MgSO4  (50%) IM  10gm  5gm  6gm  5gm 
Maintenance   dose (50%) IM   5gm 4 hrly  2.5gm 4hrly  2.5gm 4 hrly  2.5gm 6 hrly 
Total dose (gm) in 24 hrs  30   23   25   19  
 
 
DISCUSSION 
 
The  incidence  of  eclampsia  within  the  study 
period  was  2.4%  which  underscores  the 
magnitude  of  the  disease.  Other  factors  found 
associated  with  eclampsia  in  this  study  were 
young  maternal  age;  primigravidity  and  lack  of 
prenatal care which are similar to what have been 
reported by  other  workers. 
5,  6 Also  majority  of 
these patients belongs to the lower socioeconomic 
group.  84%  patients  had  body  weight  less  than 
50kg.  Pritchard  regime  was  standardized  for 
western  women,  having  total  bodymass  index 
much  higher  than  women  from  developing 
countries,  including  India.  In  present  study 
convulsions were controlled in 96% of cases with 
total dose less than 20 gms (43.18% of pritchard 
regime. In present study intramascular dose was 
reduced to 2.5gms at 6 hr interval. This did not 
affect  the  efficacy  of  regime  as  evidenced  by 
serum  Mg  levels  at  12  hrs.  However  this 
significantly  decreased  incidence  of  pain  at 
injection  site,  tissue  necrosis  and  abscess 
formation.  Rashida Begum et  al
7 in their study, 
reported  that  eclamptic  convulsions  were 
controlled  in 98%  cases  with  modified  (Dhaka) 
regime  of  magnesium  sulphate.  Results  of  the 
present  study  were  comparable  with  above 
mentioned studies. Begum MR et al
8 suggested a 
small  body  mass  index  to  be  the  reason  for 
effectiveness of  low dose regimen in  women in 
developing  countries.  There  was  no  maternal 
mortality in the present study. Perinatal mortality 
in  the  present  study  was  12%.  The  majority 
(66.7%)  of  deaths  were  stillbirths    and  33.3% 
were  neonatal  deaths.  Prematurity,  placental 
abruption  and  growth  restriction  were  common 
causes of perinatal deaths. Sardesai Suman et al 
reported  33.90%  perinatal  mortality.
9  The  mean 
serum magnesium levels remained in the range of 
4.1  to  4.35meq/lit  during  low  dose  magnesium 
sulphate  regime.  Therefore  low  dose  regimens, 
might significantly improve the safety. Moreover, 
low dose  MgSO4  might be used in cases with 
mild renal impairment which is usually present in 
these patients.  
 
CONCLUSION 
 
Associated  with  similar  efficacy  in  controlling 
convulsions  and  potentially  more  favorable 
toxicity  and  complication  rates,  the  use  of  low 
dose  MgSO4  protocols is a viable alternative to 
standard  dose  therapy.  The  dose  required  for 
control  of  a  convulsion  with  the  low  dose 
magnesiumsulphate regime was less than half of 
the  standard  Pritchard regime  making it  a  body 
friendly  regime.  However  multi-center, 
randomized controlled trials are recommended to 
test  this  proposed  regimen  to  support  routine 
clinical use low dose protocols. 
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